2022 Nelson's Pediatric Antimicrobial Therapy

For each disease, the authors provide a commentary to help select the best of all antimicrobial choices. Drug descriptions cover all antimicrobial agents available today and include complete information about dosing regimens.

TOPICS INCLUDE

• Antimicrobial Therapy by Clinical Syndromes
• Antimicrobial Therapy for Neonates
• Choosing Among
  • Antibiotics
  • Antifungal Agents
  • Antiviral Agents
  • Antiparasitic Agents
• Oral Step-down Therapy for Serious Infections
• Prevention of Symptomatic Infection
• Approach to Antibiotic Allergies
• Antibiotic Stewardship

• Updated recommendations on acute hematogenous osteomyelitis, based on newly published guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America, including information on a decrease in the incidence of MRSA infections, allowing the recommendation of cefazolin, again, in empiric therapy for most pediatric bone infections
• Updated recommendations on influenza treatment and prophylaxis, reflecting American Academy of Pediatrics guidance for 2021-2022
• Ceftazidime/avibactam now preferred over fluoroquinolones for treatment of Klebsiella pneumoniae carbapenemase-producing enteric bacilli, if susceptible
• Cefiderocol, a new iron-binding siderophore cephalosporin class, recently approved in adults for treatment of many drug-resistant pathogens, particularly Acinetobacter, Stenotrophomonas, and Pseudomonas
  under study in children
• New dosing for posaconazole suspension formulation
• New approaches to mucormycosis
• Added baloxavir for children 12+ years old
• Online updates of COVID-19 therapies once emergency use authorization in children at http: //www.aap.org/nelsons
• Updated Nelson's app also available